Filter News
Area of Research
News Type
News Topics
- (-) Biomedical (2)
- 3-D Printing/Advanced Manufacturing (3)
- Bioenergy (3)
- Composites (2)
- Computer Science (2)
- Cybersecurity (1)
- Energy Storage (1)
- Environment (2)
- Isotopes (3)
- Materials Science (7)
- Microscopy (2)
- Nanotechnology (4)
- Neutron Science (9)
- Physics (3)
- Quantum Science (2)
- Sustainable Energy (2)
- Transportation (1)
Media Contacts
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.